T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones
T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future […]
News
Reported
An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship
Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard
Scientific Publication
Our Latest Research Published in Haematologica
Great news! Our latest publication presents TE-1146 as a novel therapeutic strategy for the treatment of multiple myeloma. We are
Reported
Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution”
In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview
R&D Progress
Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its
Reported
In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology
T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of
News
T-E Meds Shortlisted for World ADC Awards – Best New Drug Developer
T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category
Meeing
Join our presentation at the Asia BIO Innovation Summit 2025
We’re proud to share that Dr. Cédric Grauffel, Manager of T-E Drug Design at T-E Meds, will be presenting at
R&D Progress
TE-1146 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case